European Journal

Lunit AI Biomarker PD-L1 Demonstrates Clinical Efficacy as Diagnostic Aid in Cancer Treatment-Published in the European Journal of Cancer

Retrieved on: 
星期四, 五月 19, 2022
Immunotherapy, Analyser, CE marking, AI, Bias, Survival, Progression-free survival, Patient, EJC, Workflow, CE, ICI, NSCLC, PD-L1, TPS, European Journal, Decision-making, Large-cell lung carcinoma, Marie Cassidy, CEO, Pharmaceutical industry, Medical device

The study has been published on May 14 in the European Journal of Cancer (EJC).

Key Points: 
  • The study has been published on May 14 in the European Journal of Cancer (EJC).
  • Findings from the study demonstrate the clinical efficacy of Lunit SCOPE PD-L1, the company's AI-powered programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) analyzer, which recently received the CE mark for commercial use in the European market.
  • Last month, Lunit SCOPE PD-L1 TPS received the CE Mark, becoming the first Lunit SCOPE product to receive regulatory approval.
  • Lunit is currently working on launching the AI software in Europe within the second half of 2022.

New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure™) Improves Muscle Strength and Exercise Performance in Middle Aged Adults

Retrieved on: 
星期二, 五月 17, 2022
Other Sports, Sports, Fitness & Nutrition, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Inflammation, Longevity, Buck Institute for Research on Aging, Parallel Walk Test, GRAS, JAMA Network Open, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Food, Doctor of Philosophy, Exercise, IRB, Swiss Federal Institute of Aquatic Science and Technology, Ageing, European Journal of Clinical Nutrition, Invention, Muscle, GameChanger, Eating, List of Nature Research journals, Mitophagy, Swiss Federal Institute of Technology, FDA, Swiss, Partnership, European Journal, Human, EPFL, Urolithin A, Nutrition, Biomarker, Health Canada, Federal Institute for Risk Assessment, Mitochondrion, Pomegranate, MD, CEO, Nature Medicine, Dietary supplement, Technology

This milestone study showed that daily intake of Amazentis proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months.

Key Points: 
  • This milestone study showed that daily intake of Amazentis proprietary Urolithin A, Mitopure, significantly improved muscle strength by 12% after four months.
  • Muscle strength in the hamstring skeletal muscle was significantly increased in both 500mg (+12%) and 1,000mg groups (+9.8%).
  • Aging is associated with a decline in mitochondrial function which can lead to reduced exercise capacity, muscle endurance and strength.
  • This study is an important milestone and shows that Urolithin A could be a gamechanger in our field.

Amphera’s MesoPher Cell Therapy Demonstrates Favourable Safety and Promising Survival in a Phase II Clinical Trial in Resected Pancreatic Cancer

Retrieved on: 
星期三, 五月 4, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, COO, Mesothelioma, EMA, Safety, Pancreatic cancer, Injection, Patient, Doctor of Philosophy, Survival, FDA, Cancer, CD40, European Journal, Reactive, Disease, CEO, HIV disease progression rates, Recurrence, Pharmaceutical industry, Medical imaging

Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Ampheras MesoPher dendritic cell therapy.

Key Points: 
  • Amphera B.V. announces positive REACtiVe Phase 2 study safety and efficacy data from the first cohort of 10 patients receiving Ampheras MesoPher dendritic cell therapy.
  • Patients, with resected pancreatic cancer who had completed standard-of-care chemotherapy, received 3 bi-weekly injections of MesoPher and booster injections at 4 and 7 months.
  • Ilona Enninga PhD, COO of Amphera said: Pancreatic cancer is notoriously challenging to treat, as the historical medical literature illustrates.
  • The REACtiVe-2 study assesses the safety and efficacy of a CD40 agonist in combination with MesoPher in patients with metastatic pancreatic cancer.

Agendia Demonstrates Accessibility and Affordability of MammaPrint® and BluePrint® in Europe at ESMO Breast Cancer 2022

Retrieved on: 
星期二, 五月 3, 2022
Biotechnology, Health, Oncology, Other Health, Innovation, European Society for Medical Oncology, Breast cancer, Senior, Woman, Development, Gene expression profiling, LDT, Blueprint, Physician, Research, Food, Oncology, ESMO, NGS, Patient, American Society of Breast Surgeons, Business development, US Food Sovereignty Alliance, European Journal, MD, Behavior, European Journal of Cancer, Prognosis, Sale, Marie Cassidy, Surgeon, Laboratory developed test, Solution, Biology, EMSO, Pathology, Recurrence, Digital, Medical imaging, Medical device, MammaPrint

This enables a more accurate decentralized solution to breast cancer care fostering worldwide accessibility to more reliable genomic testing.

Key Points: 
  • This enables a more accurate decentralized solution to breast cancer care fostering worldwide accessibility to more reliable genomic testing.
  • MammaPrint is a valuable tool to support treatment planning for breast cancer patients and with the decentralized NGS platform, this can be offered in even more countries.
  • These findings further confirm that MammaPrint and BluePrint can provide the same accurate results through NGS.
  • MammaPrint is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patients breast cancer recurrence risk.

Philogen Reports Full Year 2021 Results and Provides Corporate Update

Retrieved on: 
星期五, 四月 1, 2022
Chemical library, European Journal of Nuclear Medicine and Molecular Imaging, Disease, Blood, EDA, Glioblastoma, Cash Cash, Therapy, Ligand, Group, L19, Interleukin, ORR, Nuclear medicine, Initial public offering, Mouse, EDB, MGMT, Survival, Research, Glioma, Lomustine, Observation, Antigen, Neoplasm, IL12, Cancer, Tissue, TNF, European Journal, Inflammation, Google Images, Intellectual property, CRO, Molecular imaging, News, IL2, BST, Soft-tissue sarcoma, IPO, IL10, Patient, Partnership, Backhaus, Pharmaceutical industry, Medical imaging, Fine chemical, Cryptocurrency, Vaccine, Jaden Philogene-Bidace, Pfizer, Fibronectin, Phase

In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.

Key Points: 
  • In 2022 Philogen will limit cash burn (or possibly have no cash burn), due to existing and new partnerships, despite increased spending for clinical trials.
  • Siena (Italy), 1 April 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics, provides an update regarding the Companys full year 2021 results and recent corporate developments.
  • "We are excited for the great progress we have made following our listing on the Italian Stock Exchange in March 2021.
  • Philogen has a rich pipeline of late-stage clinical assets and continues to innovate by generating new prototypes, commented Prof. Dr. Dario Neri, Chief Executive Officer of Philogen.

Weight Loss Surgery Impact on Young Men's Testosterone Levels Underlines Bariatric Procedure Benefits, says Beverly Hills Physicians

Retrieved on: 
星期二, 三月 8, 2022
Bariatric surgery, Patient, Journal, Adult, Science, Ghrelin, Physician, University at Buffalo, Quality of life, Hospital, University, Health minister, European Journal, Man, American Medical Association, JAMA, Food, Sexual dysfunction, Obesity, Erectile dysfunction, Adolescence, Male, Lurie Children's Hospital, Female, Diabetes, Weight loss, Health, Bariatrics, European Journal of Endocrinology, Stomach, Birth control, Health insurance, Greater Los Angeles, Endocrinology

Southern California health care group Beverly Hills Physicians says that the study is one more indication of the many benefits of weight loss surgery for severely obese people of all ages and genders.

Key Points: 
  • Southern California health care group Beverly Hills Physicians says that the study is one more indication of the many benefits of weight loss surgery for severely obese people of all ages and genders.
  • It adds that members of the general public often misunderstand the nature of obesity and weight loss surgery.
  • Bariatric surgery, however, interrupts the body's normal response to food and weight loss by changing the size of the stomach.
  • Beverly Hills Physicians is a health and beauty medical group with locations throughout the Greater Los Angeles area and Southern California.

StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

Retrieved on: 
星期二, 三月 1, 2022
GLOBE, Risk, European Journal of Cancer, European Institute of Oncology, ATAC, European Institute, Industry, Breast cancer, OTC, Regulation, European Journal, Woman, Recurrence, Forward-looking statement, IEO, Patient, The Royal Marsden NHS Foundation Trust, SPRS, Royal Marsden Hospital, Pharmaceutical industry

Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.

Key Points: 
  • Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.
  • The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index.
  • In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result.
  • It is exciting that StemPrintER appears to perform as well as other commercially-available tests and indicates the potential for this novel test to inform clinical decision making.

AccuStem’s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort

Retrieved on: 
星期二, 三月 1, 2022
GLOBE, Risk, European Journal of Cancer, European Organisation for Research and Treatment of Cancer, Comparison, European Institute of Oncology, ATAC, European Institute, S, Research, Industry, Breast cancer, Biology, EJC, EORTC, Health, OTC, Regulation, European Journal, Treatment, Woman, European Society for Medical Oncology, Recurrence, Forward-looking statement, Carcinogenesis, Patient, IEO, The Royal Marsden NHS Foundation Trust, Nicola Montani, Epidemiology, SPRS, P, Royal Marsden Hospital, Pharmaceutical industry, Cancer, PHOENIX

Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.

Key Points: 
  • Results demonstrate that StemPrintER is highly prognostic for risk of distant recurrence in women with breast cancer.
  • The pivotal TransATAC study has been used to evaluate many of the commonly used breast cancer risk scoring assays, including OncotypeDX, Prosigna, EndoPredict and Breast Cancer Index.
  • In this analysis, investigators demonstrated that patients with a StemPrintER Risk Score (SPRS) Low result had significantly better outcomes than patients with a SPRS High result.
  • Comparison of stemprinter with Oncotype DX recurrence score for predicting risk of breast cancer distant recurrence after endocrine therapy.

Humacyte Announces Publication of Positive Long-Term Follow-Up Data from Phase 2 Trial of HAV™ for Hemodialysis

Retrieved on: 
星期一, 二月 28, 2022
GLOBE, Risk, Fast track (FDA), Medical University of Warsaw, Partnership, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Medical school, HUMA, Tissue, COVID-19, Company, Arteriovenous fistula, Medicine, Sale, Safety, European Journal, European Journal of Vascular and Endovascular Surgery, Form, Vibration, Manuscript, Adult, Food, Fresenius Medical Care, Terminology, Moyamoya disease, Chronic kidney disease, Intention, Dialysis, FDA, Nasdaq, Death, Forward-looking statement, Patient, Technology, Patent, Injury, HAV, AV, Infection, AVF, SEC, Pharmaceutical industry, Defense

DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that five-year data from a Phase 2 clinical trial of patients receiving the investigational Human Acellular Vessel (HAV) for arteriovenous (AV) access in hemodialysis have been published in the European Journal of Vascular and Endovascular Surgery companion journal EJVES Vascular Forum. The manuscript, entitled, “Five-year outcome in patients with end-stage renal disease who received the bioengineered human acellular vessel for dialysis access,” reports the durable long-term use and ongoing clinical function of the HAV in patients with end-stage renal disease who are undergoing hemodialysis.

Key Points: 
  • In addition, no infections of the HAV were reported during the five-year follow-up period, with the HAV being well tolerated and non-immunogenic.
  • These results indicate the potential of the HAV as a promising option for vascular access in hemodialysis.
  • As a follow-up to the Phase 2 trial described in the publication, the Company is currently conducting a Phase 3 trial in up to 240 dialysis patients.
  • The prospective Phase 2 trial evaluated the HAV in 40 adult patients with end-stage renal disease undergoing hemodialysis at three sites in Poland.

Experienced Professor Joins Trident University International's Doctor of Education Program

Retrieved on: 
星期五, 二月 11, 2022
Trident, University, Book, Doctor of Education, Learning, Trident University International, Military History Matters, European Journal, Journal, Education, Emotional intelligence, Adult, Leadership, Dr. Babasaheb Ambedkar Marathwada University, Bachelor, Higher Learning Commission, Walden University, Transition, Student, Public health, Washington University in St. Louis, Running, Doctor of Philosophy, Public policy, Administration, American, Higher, Policy, Public Policy and Administration, Research, Biophysical environment, Program, School of education, Medicine, Management, Science

CHANDLER, Ariz., Feb. 11, 2022 /PRNewswire-PRWeb/ -- Trident University International ( Trident ) is pleased to welcome new Doctoral Professor, Dr. Kennedy Maranga, to its College of Education.

Key Points: 
  • CHANDLER, Ariz., Feb. 11, 2022 /PRNewswire-PRWeb/ -- Trident University International ( Trident ) is pleased to welcome new Doctoral Professor, Dr. Kennedy Maranga, to its College of Education.
  • He will be focusing most of his energies on the Doctor of Education (Ed.D.)
  • in Educational Leadership program and the Doctor of Education (Ed.D.)
  • Founded in 1998, Trident University International is a member of the American InterContinental University System, which is accredited by the Higher Learning Commission (hlcommission.org).